Venetoclax and azacitidine in MDS patients

preview_player
Показать описание
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the use of venetoclax in combination with azacitidine for myelodysplastic syndrome patients in a Phase Ib study (NCT02966782). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Amer Zeidan
  3. Event: VJVirtual
  4. Event: EHA 2020
  5. Format: Interview
  6. Subject: Acute Myeloid Leukemia
Рекомендации по теме
Venetoclax and azacitidine 0:05:36

Venetoclax and azacitidine in MDS patients

Jacqueline Garcia: Evaluating 0:06:53

Jacqueline Garcia: Evaluating Venetoclax Plus Azacitidine in Patients with High-Risk MDS

Venetoclax plus azacitidine 0:06:58

Venetoclax plus azacitidine for higher-risk MDS

Dose modification strategies 0:02:42

Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine

Venetoclax with azacitidine 0:03:17

Venetoclax with azacitidine in HR-MDS

Venetoclax plus azacitidine 0:03:51

Venetoclax plus azacitidine in treatment-naïve and R/R MDS

Venetoclax and 5-azacytidine 0:03:03

Venetoclax and 5-azacytidine for the treatment of MDS and CMML

Venetoclax plus azacitidine 0:08:54

Venetoclax plus azacitidine in treatment-naïve higher-risk MDS

Pevonedistat, azacitidine and 0:02:20

Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML

A study of 0:01:33

A study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies

Venetoclax plus azacitidine 0:04:04

Venetoclax plus azacitidine in treatment-naïve HR-MDS

Venetoclax and Azacitidine 0:03:10

Venetoclax and Azacitidine in Newly Diagnosed AML Patients | Dan Pollyea, MD, MS | ASH 2022 #AML

Venetoclax and azacitidine 0:01:57

Venetoclax and azacitidine for AML ineligible for standard induction

Venetoclax & azacitidine 0:01:22

Venetoclax & azacitidine for AML in 2020

Real-world data on 0:02:21

Real-world data on venetoclax-based regimens for patients with AML or MDS with excess blasts-2

Phase Ib study 0:02:18

Phase Ib study of venetoclax plus azacitidine in patients with R/R MDS

TakeAim Leukemia: emavusertib 0:01:23

TakeAim Leukemia: emavusertib as monotherapy or with azacitidine or venetoclax in R/R AML or MDS

Venetoclax + Azacitidine 0:07:01

Venetoclax + Azacitidine in Frontline AML Management

Result of venetoclax 0:01:56

Result of venetoclax plus/minus azacitidine for R/R MDS

Pevonedistat, venetoclax and 0:02:50

Pevonedistat, venetoclax and azacitidine for older AML patients

Azacitidine and Venetoclax 0:03:36

Azacitidine and Venetoclax for High-risk #MDS Patients | Jacqueline S. Garcia, MD | ASH 2023

Venetoclax and magrolimab 0:02:53

Venetoclax and magrolimab for treatment of AML and MDS

Venetoclax with decitabine 0:02:05

Venetoclax with decitabine for high-risk AML and MDS

Venetoclax in combination 0:05:52

Venetoclax in combination with azacitidine for patients with treatment-naïve HR-MDS